Elmind Capital LP Invests $3.26 Million in Supernus Pharmaceuticals, Inc. $SUPN

Elmind Capital LP acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 70,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,255,700. Supernus Pharmaceuticals accounts for approximately 0.0% of Elmind Capital LP’s portfolio, making the stock its 25th largest holding. Elmind Capital LP owned about 0.12% of Supernus Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. ADAR1 Capital Management LLC acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $1,295,000. Hsbc Holdings PLC acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at about $424,000. PDT Partners LLC bought a new position in Supernus Pharmaceuticals during the second quarter worth $1,203,000. Canada Pension Plan Investment Board bought a new position in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $823,000. Finally, Legal & General Group Plc acquired a new stake in shares of Supernus Pharmaceuticals during the second quarter worth approximately $6,299,000.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock traded down $0.68 during mid-day trading on Friday, reaching $43.51. 342,032 shares of the company were exchanged, compared to its average volume of 757,727. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $42.45 and a fifty-two week high of $59.68. The company has a market capitalization of $2.53 billion, a P/E ratio of -22.66, a P/E/G ratio of 0.83 and a beta of 0.56. The business’s 50 day simple moving average is $46.83 and its 200 day simple moving average is $48.69.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The company had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. During the same period in the prior year, the company posted $0.40 EPS. The business’s revenue was up 32.4% on a year-over-year basis. On average, analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on SUPN shares. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 6th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald increased their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $62.83.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.